BioCentury
ARTICLE | Clinical News

Z160: Development discontinued

November 18, 2013 8:00 AM UTC

Zalicus discontinued development of Z160 after top-line data from a pair of double-blind, U.S. Phase IIa trials to treat chronic neuropathic pain showed that twice-daily 375 mg oral Z160 missed the primary endpoint in both trials of improving average weekly pain score based on PI-NRS from baseline to week 6 vs. placebo. One trial enrolled 144 patients with postherpetic neuralgia (PHN) and the other enrolled 141 patients with lumbosacral radiculopathy. Z160 was well tolerated with no treatment-related adverse events reported. Zalicus said it will now focus on developing Z944, a T-type calcium channel blocker for which the company plans to start Phase II testing to treat pain next year. ...